Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners; Scott Hutton Joins Biodesix
Innovatus Capital partners joins as a new investor; Scott Hutton joins as COO
Biodesix and Professor Fred R. Hirsch announced a collaboration on a PD-L1 study
Media Advisory: Dr. Heinrich Roder, Biodesix CTO, to speak at precision medicine world conference
Data Published In AACR Journal Suggest Biodesix® Test in Development May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors
Findings in the AACR Journal on melanoma patient outcomes after anti PD1 therapy; a serum protein signature predicted survival.
Biodesix leaders shared commercial and pipeline updates at the annual qPCR and dPCR Congress
Biodesix Announces New Data Demonstrating Analytic Validity of Automated RNA Extraction from Plasma with the GeneStrat® Test
Biodesix announces new data, presented at AMP2017, supporting the analytic validity of automated RNA extraction with the GeneStrat test
Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients
Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients
Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry
Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC
Biodesix will present posters and an oral presentation of data at SITC 2017 Annual Meeting.
2018 Preliminary Private Payor Rate-Based Payment Amounts Released for Clinical Diagnostic Laboratory Tests; Biodesix Commends CMS for Committing to On-Time PAMA Implementation
Biodesix commended the Centers for Medicare & Medicaid Services (CMS) for publishing preliminary 2018 rates for clinical diagnostic laboratory tests.